
Raycaster provides an AI-native document workspace that helps biopharma companies accelerate commercial wins, R&D, and intellectual property work. The platform uses AI agents and natural language understanding to extract insights from documents and data—supporting tasks like surfacing purchase-ready accounts, automating RFP responses, analyzing clinical trials, and monitoring patent landscapes. It is positioned as a B2B SaaS product for biopharma providers and instrument makers, integrating with commercial and regulatory workflows and common enterprise tools. Raycaster’s core technologies include large language models for document understanding and analytics focused on IP intelligence, competitive analysis, and lab/instrument specifications.

Raycaster provides an AI-native document workspace that helps biopharma companies accelerate commercial wins, R&D, and intellectual property work. The platform uses AI agents and natural language understanding to extract insights from documents and data—supporting tasks like surfacing purchase-ready accounts, automating RFP responses, analyzing clinical trials, and monitoring patent landscapes. It is positioned as a B2B SaaS product for biopharma providers and instrument makers, integrating with commercial and regulatory workflows and common enterprise tools. Raycaster’s core technologies include large language models for document understanding and analytics focused on IP intelligence, competitive analysis, and lab/instrument specifications.
Company: Raycaster (legal name: 7th Ave Labs, Inc.) — AI-native document/workspace for life sciences and biopharma
Founded: 2024
Headcount: 4 employees (profileed count)
Funding: Pre-Seed (Dec 4, 2024) — investors: Y Combinator, SAV (Scale Asia Ventures)
Product focus: Evidence-backed research, document understanding, IP intelligence, commercial & regulatory workflows
Life sciences / biopharma document and research workflows including IP intelligence, competitive analysis, and lab/instrument specification discovery.
2024
Biotechnology
500000
Investors listed: Y Combinator and SAV (Scale Asia Ventures)
“YC-backed (Y Combinator lead) and SAV (Scale Asia Ventures)”
| Company |
|---|
NYC · In-person (Hudson Yards) · Base + aggressive commission + equity
Raycaster is the first AI-native document workspace (Cursor for Documents) for high-stakes work, starting in life sciences (CMC, quality, regulatory). Instead of 47 versions of a Word doc in someone’s inbox, customers get a single living dossier: thousand-page PDFs, flows, and clinical data in one place - searchable and kept in sync.
We’re backed by YC, leading life sciences investors (behind companies like Oscar Health and Mammoth Bio), and execs from Definitive Healthcare, Colossal Biosciences, and IQVIA. We’re already working with enterprise customers globally. The product resonates - now we’re hiring our first GTM to turn early demand into a repeatable machine.
Competitive base + aggressive commission (high upside if you close).
Way above market equity, real path head of GTM and C-suite.
To apply, send a short note to founders *at*raycaster.ai with one deal you personally closed (who, price, cycle time) and exactly how you got it done.